RESULTS	Among 467 participants in the modified intent-to-treat population , at the primary endpoint at week 28 , the seroprotection rate ( SPR : % with anti-HBs10mIU / mL ) in the HBsAg-1018 group ( 89.9 % ) met criteria for noninferiority and superiority to the SPR in the HBsAg-Eng group ( 81.8 % ) .\